Obsidian Therapeutics, Inc. (OBX)

Obsidian Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-97.23	-105.67	-91.26
Net Income Net Income Growth	-94.22	-100.61	-83.11
Earnings Per Share EPS Growth	-4.25	-2056.18	-
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	34.45	80.49	168.27
Total Debt Total Debt Growth	2.91	4.28	6.81
Net Cash (Debt) Net Cash Growth	31.54	76.2	161.46
Net Cash Growth	-	-52.80%	-
Net Cash Per Share Net Cash Per Share Growth	1.42	1557.42	-

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-91.81	-90.39	-75
Capital Expenditures CapEx Growth	-0.02	-0.07	-0.78
Free Cash Flow Free Cash Flow Growth	-91.83	-90.47	-75.78
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error